KEYNOTE 522 Subgroup Analyses
KEYNOTE-522: Biomarker and OS Subgroup Analyses of Neoadjuvant Pembrolizumab + CT Followed by Adjuvant Pembrolizumab in High-Risk Early TNBC

Released: December 16, 2024

Expiration: June 15, 2025

Activity

Progress
1
Course Completed